Qualigen Therapeutics Promotes Amy Broidrick to President
December 14 2021 - 9:18AM
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company
focused on developing treatments for adult and pediatric cancers
with potential for Orphan Drug Designation, today announces a key
executive promotion. The company has named Amy Broidrick as
President and Chief Strategy Officer. Ms. Broidrick will also
continue in her role as a Director. Michael Poirier, who had
previously been serving as
Chairman, President and Chief Executive Officer, will continue to lead the company as Chief Executive Officer, and Chairman of the Board.
Ms. Broidrick joined the Board of Directors of
Qualigen Therapeutics in August 2020, and was later appointed
Executive Vice President, Chief Strategy Officer in December
2020.
“We are thrilled to promote Amy to President of
Qualigen, as she has been instrumental in guiding our strategy and
operations for some time, including the advancement of our oncology
pipeline programs QN-247 and RAS-F and the execution of our
financial strategy to support our continued progress,” commented
Michael Poirier, Qualigen’s Chief Executive Officer.
Ms. Broidrick has over 26 years experience in
the biopharmaceutical industry in a variety of functions and
increasing responsibility. Ms. Broidrick served from 2016 to 2020
as Senior Vice President, Global Head of Corporate Development of
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical
company where she was responsible for building and implementing the
US and global corporate and business development functions. Before
that, she was Vice President, Head of Global Marketing Excellence
and Business Innovation with EMD Serono (part of Merck KGaA).
Earlier, she was Vice President, Head of Marketing and
Commercialization at Arena Pharmaceuticals, Inc., and held roles of
increasing responsibility at Merck & Co. and Pfizer (formerly
GD Searle) including Global Brand Leader with worldwide P&L
accountability. Ms. Broidrick holds a BA from Fairleigh Dickinson
University, completed further undergraduate studies at Wroxton
College in England, and performed post-graduate work at Fairleigh
Dickinson.
“I have long believed in the potential of
Qualigen to develop our promising oncology pipeline toward IND
applications for ultimately differentiated therapeutics for adult
and pediatric cancer patients, coupled with the opportunity to
further our FastPack diagnostic business. I am honored to
collaborate closely with the team to deliver on these goals,” added
Ms. Broidrick.
About Qualigen
Therapeutics, Inc.
Qualigen Therapeutics, Inc. is a biotechnology
company focused on developing treatments for adult and pediatric
cancers with potential for Orphan Drug Designation, as well as
maintaining and expanding its core FDA-approved FastPack® System,
which has been used successfully in diagnostics for 20 years.
Qualigen’s aptamer platform, of which QN-247 is the lead candidate,
inhibits nucleolin, a key multi-functional regulatory protein that
is overexpressed in cancer cells, thus influencing their
proliferation, survival, and metastasis. QN-247 has shown promise
in pre-clinical studies for the treatment of acute myeloid leukemia
(AML). Qualigen’s RAS-F platform is a family of RAS oncogene
protein-protein interaction inhibitor small molecules that is
believed to disrupt pathways for cancer genes that cause tumor
formation. Such mechanism of action may be effective in the
treatment of about one quarter of all cancers, including certain
forms of pancreatic, colorectal, and lung cancers. The RAS pathway
has generated considerable interest due to recent breakthrough
developments in the field and the first clinical approval earlier
this year for a K-RAS directed drug. In addition to its oncology
drug pipeline, Qualigen has an established diagnostics business
which manufactures and distributes proprietary and highly accurate
rapid blood testing systems for the management of prostate cancer
and other diseases and health conditions. Qualigen’s management has
significant experience in drug and medical device development,
manufacturing, marketing, and distribution.
For more information about Qualigen Therapeutics, Inc. please
visit www.qualigeninc.com.
Forward-Looking Statements
This news release contains forward-looking
statements by the Company that involve risks and uncertainties and
reflect the Company's judgment as of the date of this release.
These statements include those related to the Company's prospects
and strategy for the development of therapeutic drug candidates.
Actual events or results may differ from the Company's
expectations. For example, there can be no assurance that the
Company will develop any drugs (including QN-247 and RAS-F); that
preclinical or clinical development of the Company's drugs
(including QN-247 and RAS-F, and deprioritized infectious-disease
programs such as QN-165) will be completed on any projected
timeline or will be successful; that any clinical trials will be
approved to begin by or will proceed as contemplated by any
projected timeline; that future clinical trial data will be
favorable or that such trials will confirm any improvements over
other products or lack negative impacts; that any drugs will
receive required regulatory approvals (including Orphan Drug
status) or that they will be commercially successful; that patents
will issue on the Company's owned and in-licensed patent
applications; that such patents, if any, and the Company's
currently owned and inlicensed patents would prevent competition;
that the Company will be able to procure or earn sufficient working
capital to complete the development, testing and launch of the
Company's prospective therapeutic products (including QN-247 and
RAS-F, and any repositioning of QN-165); or that the Company will
be able to maintain or expand market demand and/or market share for
the Company's diagnostic products. The Company's stock price could
be harmed if any of the events or trends contemplated by the
forward-looking statements fails to occur or is delayed or if any
actual future event otherwise differs from expectations. Additional
information concerning these and other risk factors affecting the
Company's business can be found in the Company's prior filings with
the Securities and Exchange Commission, including its most recent
Form 10-K, all of which are available at www.sec.gov.
The Company disclaims any intent or obligation
to update these forward-looking statements beyond the date of this
news release, except as required by law. This caution is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
Investor Relations:
David Kugelman Atlanta Capital Partners, LLC(404) 856-9157 or
(866) 692-6847 Toll Free - U.S. & Canadadk@atlcp.com
Tony SchorInvestor Awareness, Inc.(847)
971-0922tony@investorawareness.com
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Apr 2023 to Apr 2024